Hematologic Neoplasms
Conditions
Keywords
Cancer, microbiome, high dose chemotherapy, stem cell transplantation, CAR-T cell
Brief summary
Numerous in vitro and animal studies as well as growing number of clinical studies support the important role of microbiome in carcinogenesis and cancer treatment. Detection of changes in patients´ microbiome following hematopoietic cell transplantation/CAR-T cell therapy and correlations with adverse transplant outcomes, mainly infectious complications, acute and chronic GvHD, disease recurrence etc. could serve as predictive markers of immune recovery and treatment response.
Detailed description
Currently, available findings coming mainly from allo-HSCT (hhematopoietic cell transplantation) studies, link particular changes in microbiota with overall survival and post-transplant disorders, especially GvHD. According to limited data, further evaluation of associations between the alterations in microbiome composition and toxicities. Detail investigation of both the microbiome and host immune system may help to find microbiome markers useful for very early identification of patients at risk for major transplant-related complications. This might bring the possibility to modulate the gut microbiota in patient´s specific manner to achieve optimal therapeutic outcome and follow-up, while avoiding severe post-transplant complications. This is prospective, single center, non-randomized, hypothesis generating study. Patients will be asked to provide a sample of blood, urine and stool. This blood will be used for plasma and serum banking for further analysis, including micro RNA (miR) and chemokine detection. Stool will be used for microbiome studies - isolation of total DNA/RNA and 16S (RNA component of the small subunit of a prokaryotic ribosome) rRNA (ribosomal ribonucleic acid) gene sequencing for bacterial taxonomic classification. Furthermore, metagenomic sequencing and subsequent taxonomic and functional classification of microbial genes will be used including characterization of potentially clinically relevant features of the microbiome such as antibiotic resistance and microbial virulence factors.
Interventions
OTHERBlood, urine and stool sampling
Sampling of blood and urine for miR and chemokine detection. Sampling of stool for for microbiome studies.
Sponsors
Slovak Academy of Sciences
National Cancer Institute, Slovakia
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* signed written informed consent * aged 18 years or older * patients planned to be treated by high-dose chemotherapy and hematopoietic cell transplantation or by CAR-T cell therapy in National Cancer Institute, Slovakia
Exclusion criteria
\- patients not-matching inclusion criteria
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Microbial changes in stool as measured by 16S rRNA gene sequencing in hematological cancer patients before, at time and after hematopoietic cell transplantation and CAR-T cell therapy | 100 days | Microbial changes of stool will be assessed before, at time and after hematopoietic cell transplantation and CAR-T cell therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To correlate microbial changes in stool as measured by 16S rRNA gene sequencing with the post-transplant complications in auto and allogeneic transplant settings (GvHD, diarrhea, infectious complications) and in CAR-T cell therapy | 100 days | To assess microbial changes with toxicity of therapy |
| To correlate microbial changes in stool as measured by 16S rRNA gene sequencing with the patients reported outcomes. | 100 days | To correlate microbial changes with the quality of life, spirituality, cognitive functions |
| To correlate microbial changes in stool as measured by 16S rRNA gene sequencing with the patients nutrition status | 100 days | To correlate microbial changes with the patients nutrition. |
Countries
Slovakia
Contacts
Primary ContactBarbora Kašperová, MD
Backup ContactSona Ciernikova, PhD
Outcome results
None listed